The past decade has witnessed significant advances in our understanding of the biology of prostate cancer.
Androgen ablation/androgen receptor inhibition remains as the mainstay of treatment for advanced prostate cancer. Our understanding of the biology of prostate cancer has increased exponentially owing to advances in molecular biology. With this knowledge many intriguing issues have come to light, which clinicians and scientists alike strive to answer. These include why prostate cancer is so common, what drives the development of prostate cancer at a molecular level, why prostate cancer appears refractory to many families of cytotoxic chemotherapeutics, and why prostate cancer preferentially metastasizes to bone. Two clinical forms of prostate cancer have been identified: indolent organ confined disease, which elderly men often die of, and aggressive metastatic disease. A method of distinguishing between these two forms of the disease at an organ-confined stage remains elusive. Understanding the mechanisms of castrate resistance is a further issue of clinical importance. New trials of treatments, including molecular agents that target prostate cancer from a range of angles, have been instituted over the past 10-15 years. We can look at these trials not only as a chance to investigate the effectiveness of new treatments but also as an opportunity to further understand the complex biology of this disease.
Written by:
O'Hanlon Brown C, Waxman J. Are you the author?
Department of Surgery and Cancer, Division of Cancer, Imperial College London, UK.
Reference: Br J Radiol. 2012 Nov;85 Spec No 1:S28-40.
doi: 10.1259/bjr/13017671
PubMed Abstract
PMID: 23118100
UroToday.com Prostate Cancer Section
